The latest News Headlines from the Scientific, Research and HighTech world

Články z PhysOrgType 2 diabetes medication rosiglitazone associated with increased cardiovascular risks and death

28. 6 2010 (17:23)

A new study published online today by JAMA shows that among patients age 65 years and older, rosiglitazone (a medication for treating Type 2 diabetes) is associated with an increased risk of stroke, heart failure, and all-cause mortality (death) when compared with pioglitazone (another medication for diabetes). The study was published online today in advance of an upcoming Food and Drug Administration meeting that will review the safety of rosiglitazone. The paper will appear in the July 28 print issue of JAMA.